INTRODUCTION
============

Beta blockers have been the standard treatment for patients with acute myocardial infarction (AMI). Beta blockers have the beneficial effects which reduced ischemia, blood pressure, fatal arrhythmia, and thrombosis.[@B1][@B2][@B3][@B4] Guidelines had been established mostly based on randomized trials before reperfusion era. In the era of percutaneous coronary intervention (PCI), there was no prospective randomized trial to show the efficacy of beta blocker therapy on clinical outcomes in AMI patients. In addition, several observational studies have showed inconsistent results.[@B5][@B6] With evidences of accumulating recent evidences, practical guidelines differ in terms of recommendations regarding indication and duration of beta blockers. In addition, continuous use of beta blocker is often impossible due to adverse drug effect. There was remained unsolved issue whether beta blocker use beyond 1 year after AMI improved outcomes in the reperfusion era. Therefore, we investigated the association of beta blocker therapy with clinical outcomes in patients with AMI who underwent PCI, using a nationwide cohort study using an insurance claims database.

METHODS
=======

Study population
----------------

This study is designed as a retrospective cohort using claim data of Korean National Health Insurance Service (KNHIS). The KNHIS as the single insurer of Korean National Health Insurance Program (KNHIP) is currently operating a medical claim database including not only diagnosis, prescription and procedure but also personal data such as age, gender, residential area or the date of death. All of medical service providers and population in Korea have an obligation to join the KNHIP according to national acts. Therefore, the KNHIS database covers almost all of medical behaviors performed in the whole Korean population since 2002. The database is based on Korean Standard Classification of Disease (KCD) 7 code system which is very similar with the International Statistical Classification of Diseases and Related Health Problems (ICD) 10 code system. From 2005 to 2014, we included the lifetime-first users of coronary bare metal or drug eluting stent with diagnostic code of AMI (I21, I22 I23) using the KNHIS database. The exclusion criteria are as follows. 1) no coronary stent implantation, 2) cardiopulmonary resuscitation, 3) all death within 3 months, 4) chronic obstructive pulmonary disease, 5) previous diagnosis of metastatic cancer. In addition, we excluded the patients who never had any anti-platelet agents during follow-up in order to minimize the confounding factor related with the loss of follow-up. The study population was followed for 2 years or until primary end points after stent implantation.

Measurement of variables
------------------------

The measurement of variables was performed analyzing diagnostic, prescription and procedural code in claim data. We used medical possession rate (MPR) which is calculated as dividing prescription duration by follow-up duration in order to identify long-term use pattern of beta blocker. We classified study population into regular users (MPR ≥80%), irregular users (1--79%), non-users (0%) according to MPR during follow up.[@B7] Baseline characteristics of underlying disease were considered pre-diagnosed if individuals had two consequent diagnoses in out-patient clinic or a single diagnosis during hospitalization. We calculated Charlson comorbidity score which definition was following the Quan\'s previous study.[@B8] The detailed working definitions of all variables in this study are listed in [Supplementary Table 1](#S1){ref-type="supplementary-material"}. The primary end point of this study is the composite of all-cause death, followed myocardial infarction (MI) or all type of stroke. The definition of followed MI is the combination of the main diagnosis of AMI (diagnostic code: I21, I22, I23) confirmed by coronary angiography (procedure code: HA670) during rehospitalization or newly diagnosed sudden cardiac arrest (diagnostic code: I469). We used narrow definition of AMI in order to minimize false-positive detection related with misdiagnosis of previous old MI. All types of stroke include ischemic, hemorrhagic or unknown type of stroke (diagnostic code: I60--64) confirmed with imaging study (examination code: HE101, 201, 135, 235, 236, 451, 461) during hospitalization.

Statistical analysis
--------------------

The χ^2^ test or Fisher\'s exact test were used to compare categorical variables. The student t-test was conducted to compare continuous variables. Univariate and distributional analysis included measures of clinical outcomes. For propensity score matching (PMS), we performed a 1:1 case-control match on the propensity score with a hierarchical sequence until no more matches made. SAS Logistic procedure code was used to create the propensity score. A multivariate Cox proportional-hazards regression model was used to determine the effect of beta blocker as an independent predictor of outcomes. Covariates for the adjustment were selected using multivariate regression analysis. The following variables were included in the Cox proportional-hazard regression model as confounding factors; age, sex, year of study enrollment, hypertension, diabetes mellitus, dyslipidemia, previous stroke, previous MI, heart failure, history of malignancy, stent type, number of stents, in hospital and followed medications (dual antiplatelet, angiotensin II receptor blockers \[ARB\] or angiotensin converting enzyme \[ACE\] inhibitor, calcium channel blocker, statin, loop diuretics, and spironolactone). Statistical analysis was performed using the SAS software (SAS institute, ver 9.1, Cary, NC, USA). The statistical significance level was p\<0.05.

Ethic statement
---------------

The study protocol was approved by Chung-Ang University Hospital Institutional Review Board (1601-005-254). Informed consent was waived by Institutional Review Board because this study was based on the KNHIS database which was fully anonymized.

RESULTS
=======

Prescription rate of beta blocker
---------------------------------

We identified a total of 81,752 patients that met eligible criteria for the period between January 2005 and December 2014. Overall, 63,885 (78%) patients were prescribed beta blockers and 17,867 (22%) were not prescribed at discharge ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). There was a trend of increase use of beta blockers from 70% in 2005 to 78% in 2014. Among prescribed beta blockers at discharge, the most commonly prescribed medication was carvedilol (52%), followed by bisoprolol (22%). Overall for 2 years, regular users were 53,991 (66%) of patients and non-users were 10,991 (13%). Regular use of beta blockers has been gradually increased from 57% in 2005 to 69% in 2014. During the follow-up, most commonly prescribed agent was carvedilol (45%), followed by bisoprolol (24%).

###### Trends in the use of beta-blockers during hospitalization in patients with AMI underwent coronary stent insertion
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  User types         Overall          2005            2006            2007            2008            2009            2010           2011            2012            2013            2014
  ------------------ ---------------- --------------- --------------- --------------- --------------- --------------- -------------- --------------- --------------- --------------- ---------------
  User               63,885 (78.14)   4,158 (69.65)   5,437 (71.56)   5,790 (74.59)   5,950 (77.62)   6,531 (81.66)   6,898 (85.6)   6,258 (78.18)   7,064 (81.06)   7,619 (80.17)   8,180 (78.07)
  Non-user           17,867 (21.86)   1,812 (30.35)   2,161 (28.44)   1,972 (25.41)   1,716 (22.38)   1,467 (18.34)   1,160 (14.4)   1,747 (21.82)   1,650 (18.94)   1,884 (19.83)   2,298 (21.93)
  Overall patients   81,752           5,970           7,598           7,762           7,666           7,998           8,058          8,005           8,714           9,503           10,478

Values are presented as number of patients (%).

AMI = acute myocardial infarction.

###### Prescription pattern of beta-blockers in patients with AMI underwent coronary stent implantation
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  User types       Overall          2005            2006            2007            2008            2009            2010            2011            2012            2013            2014
  ---------------- ---------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  Regular user     53,991 (66.04)   3,398 (56.92)   4,447 (58.53)   4,846 (62.43)   4,938 (64.41)   5,313 (66.43)   5,625 (69.81)   5,539 (69.19)   6,180 (70.92)   6,523 (68.64)   7,182 (68.54)
  Irregular user   16,770 (20.51)   1,329 (22.26)   1,689 (22.23)   1,634 (21.05)   1,577 (20.57)   1,706 (21.33)   1,642 (20.38)   1,597 (19.95)   1,674 (19.21)   1,952 (20.54)   1,970 (18.8)
  Non-user         10,991 (13.44)   1,243 (20.82)   1,462 (19.24)   1,282 (16.52)   1,151 (15.01)   979 (12.24)     791 (9.82)      869 (10.86)     860 (9.87)      1,028 (10.82)   1,326 (12.66)

Values are presented as number of patients (%).

AMI = acute myocardial infarction.

Baseline characteristics
------------------------

Overall, mean age was 60 years old and male was 76%. ([Table 3](#T3){ref-type="table"}) The second-generation drug eluting stent was deployed in 66% and bare metal stent was used in 4.4%. Single stent was implanted in 83% of patients. Prescription rate was 91% of dual antiplatelet therapy, 78% of ARB or ACE inhibitors and 82% of statin at discharge. Compared with no use of beta blockers, regular users were younger, treated more frequently with the second-generation drug eluting stent, had more hypertension and less diabetes mellitus and were prescribed less dual antiplatelet therapy, more ARBs or ACE inhibitors and statin, less spironolactone at discharge. During follow up, regular users were also prescribed more ARBs or ACE inhibitors, but less dual antiplatelet therapy and similar spironolactone.

###### Baseline characteristics according to pattern of beta blocker use
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  Baseline characteristics       Regular user (n=53,991)       Irregular user (n=16,770)   Non-user (n=10,991)   p (all 3)        p (1 vs.2)   p (2 vs.3)   p (1 vs.3)   
  ------------------------------ ----------------------------- --------------------------- --------------------- ---------------- ------------ ------------ ------------ ----------
  Age (year)                     60 (51--69)                   61 (51--71)                 62 (52--71)           \-               \-           \-           \-           
  Male                           41,426 (76.73)                12,477 (74.40)              8,243 (75.00)         \<0.0001         \<0.0001     0.2635       \<0.0001     
  Study enrollment                                                                                               \<0.0001         \<0.0001     \<0.0001     \<0.0001     
                                 2005--2008                    17,629 (32.65)              6,229 (37.14)         5,138 (46.75)                                           
                                 2009--2011                    16,477 (30.52)              4,945 (29.49)         2,639 (24.01)                                           
                                 2012--2014                    19,885 (36.83)              5,596 (33.37)         3,214 (29.24)                                           
  Underlying medical condition                                                                                                                                           
                                 Hypertension                  26,685 (49.42)              7,944 (47.37)         5,135 (46.72)    \<0.0001     \<0.0001     0.2885       \<0.0001
                                 DM                            14,656 (27.15)              4,708 (28.07)         3,090 (28.11)    0.0164       0.0185       0.9422       0.0377
                                 Dyslipidemia                  14,653 (27.14)              4,494 (26.8)          3,094 (28.15)    0.0392       0.3841       0.0134       0.0302
                                 Previous stroke, all type     3,968 (7.35)                1,564 (9.33)          1,024 (9.32)     \<0.0001     \<0.0001     0.9788       \<0.0001
                                 Previous MI                   1,728 (3.20)                705 (4.20)            526 (4.79)       \<0.0001     \<0.0001     0.0213       \<0.0001
                                 CHF                           2,340 (4.33)                912 (5.44)            563 (5.12)       \<0.0001     \<0.0001     0.2511       0.0003
                                 History of malignancy         1,363 (2.52)                518 (3.09)            317 (2.88)       0.0002       \<0.0001     0.3289       0.0303
  Charlson comorbidity score     1 (0--2)                      1 (0--2)                    1 (0--2)              \<0.0001         \<0.0001     0.0265       0.0005       
                                 ≤1                            36,729 (68.03)              11,030 (65.77)        7,287 (66.30)                                           
                                 2--3                          10,364 (19.20)              3,245 (19.35)         2,149 (19.55)                                           
                                 4--5                          4,821 (8.93)                1,640 (9.78)          1,082 (9.84)                                            
                                 ≥6                            2,077 (3.85)                855 (5.10)            473 (4.30)                                              
  Type of stent                                                                                                  \<0.0001         \<0.0001     \<0.0001     \<0.0001     
                                 BMS                           2,262 (4.19)                766 (4.57)            592 (5.39)                                              
                                 1st generation DES            14,902 (27.60)              5,262 (31.38)         4,044 (36.79)                                           
                                 2nd generation DES            36,827 (68.21)              10,742 (64.05)        6,355 (57.82)                                           
  Number of stents                                                                                               0.0288           0.0047       0.1918       0.7611       
                                 1                             4,4670 (82.74)              13,922 (83.02)        9,088 (82.69)                                           
                                 2                             6,096 (11.29)               1,770 (10.55)         1,228 (11.17)                                           
                                 ≥3                            3,225 (5.97)                1,078 (6.43)          675 (6.14)                                              
  In-hospital medication                                                                                                                                                 
                                 Dual antiplatelet agent       48,896 (90.56)              15,261 (91.00)        10,044 (91.38)   0.0125       0.0881       0.2729       0.0069
                                 RAAS blocker                  43,658 (80.86)              12,835 (76.54)        7,149 (65.04)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 Beta-blocker                  48,524 (89.87)              12,850 (76.62)        2,511 (22.85)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 CCB                           2,021 (3.74)                786 (4.69)            630 (5.73)       \<0.0001     \<0.0001     0.0001       \<0.0001
                                 Statin                        44,834 (83.04)              1,692 (81.65)         8,733 (79.46)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 High intensity statin         14,755 (27.33)              4,125 (24.60)         2,073 (18.86)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 Thiazide                      1,510 (2.80)                600 (3.58)            402 (3.66)       \<0.0001     \<0.0001     0.7276       \<0.0001
                                 Loop diuretics                7,963 (14.75)               3,010 (17.95)         2,033 (18.50)    \<0.0001     \<0.0001     0.2466       \<0.0001
                                 Spironolactone                5,683 (10.53)               2,085 (12.43)         1,272 (11.57)    \<0.0001     \<0.0001     0.0316       0.0012
                                 Vasodilators                  27,255 (50.48)              8,619 (51.40)         5,935 (54.00)    \<0.0001     0.0385       \<0.0001     \<0.0001
                                 Vasopressor                   9,322 (17.27)               3,129 (18.66)         2,335 (21.24)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
  Followed medication                                                                                                                                                    
                                 Dual antiplatelet agent       31,584 (58.50)              8,369 (49.90)         6,745 (61.37)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 Aspirin users                 15,556 (28.81)              4,276 (25.50)         2,693 (24.50)                                           
                                 Clopidogrel users             6,363 (11.79)               1,760 (10.49)         1,008 (9.17)                                            
                                 No antiplatelet agents        488 (0.90)                  2,365 (14.10)         545 (4.96)                                              
                                 RAAS blocker                  39,369 (72.92)              6,784 (40.45)         6,089 (55.40)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 CCB                           4,192 (7.76)                967 (5.77)            1,026 (9.33)     \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 Statin                        46,501 (86.13)              8,948 (53.36)         7,991 (72.70)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 High intensity statin         11,962 (22.16)              3,329 (19.85)         1,541 (14.02)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 Thiazide                      2,580 (4.78)                498 (2.97)            569 (5.18)       \<0.0001     \<0.0001     \<0.0001     0.0762
                                 Loop diuretics                5,535 (10.25)               1,287 (7.67)          1,195 (10.87)    \<0.0001     \<0.0001     \<0.0001     0.0515
                                 Spironolactone                3,014 (5.58)                571 (3.40)            612 (5.57)       \<0.0001     \<0.0001     \<0.0001     0.9528
                                 Vasodilators                  18,320 (33.93)              3,999 (23.85)         4,088 (37.19)    \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 Number of antihypertensives   1.85±0.59                   0.49±0.62             0.70±0.67        \<0.0001     \<0.0001     \<0.0001     \<0.0001
                                 Number of antihypertensives   2 (2--2)                    0 (0--1)              1 (0--1)         \-           \-           \-           \-

Values are expressed as median (interquartile range), number (%), or mean±standard deviation.

BMS = bare metal stent; CCB = calcium channel blocker; CHF = congestive heart failure; DES = drug-eluting stent; DM = diabetes mellitus; MI = myocardial infarction; RAAS = Renin-angiotensin-aldosterone system.

Clinical outcomes
-----------------

A total of 10,624 patients at each group were matched on the basis of propensity score ([Table 4](#T4){ref-type="table"}). The baseline characteristics after matching were well balanced. In multivariate regression analysis, age, sex, underlying disease, type of stents, and medications were independent predictors ([Table 5](#T5){ref-type="table"}). In the matched population, regular beta blocker use was associated with a 29% reduced risk of composite adverse events (all death, MI or stroke) (hazard ratio \[HR\], 0.717; 95% confidence interval \[CI\], 0.650--0.791; p\<0.001; [Table 6](#T6){ref-type="table"}). Compared to no use of beta blocker, regular use significantly reduced all death (HR, 0.622; 95% CI, 0.543--0.714; p\<0.001) and MI (HR, 0.705; 95% CI, 0.059--0.842; p=0.001), but did not reduce stroke (HR, 1.05; 95% CI, 0.847--1.303; p=0.654).

###### Baseline characteristics before and after propensity score matching
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  Risk factors                   Before matching (n=64,982)   After matching (n=21,248)                                                                                                       
  ------------------------------ ---------------------------- --------------------------- --------------- ---------- ---------------------- ---------------------- --------------- ---------- ----------
  Followed duration (month)      24.33 (21.43--24.33)         24.33 (18.03--24.33)        0.14            \-         24.33 (21.53--24.33)   24.33 (18.07--24.33)   0.11            \-         
  Age (year)                     60 (51--69)                  62 (52--71)                 −0.15           \-         62 (52--71)            61 (52--71)            −0.01           \-         
  Male                           41,426 (76.73)               8,243 (75.00)               0.03            \<0.0001   7,988 (75.19)          7,991 (75.22)          0.00            \<0.0001   
  Study enrollment                                                                                        \<0.0001                                                                 0.8109     
                                 2005--2008                   17,629 (32.65)              5,138 (46.75)   −0.24      4,886 (45.99)          4,930 (46.40)          −0.01                      
                                 2009--2011                   16,477 (30.52)              2,639 (24.01)   0.12       2,589 (24.37)          2,557 (24.07)          0.01                       
                                 2012--2014                   19,885 (36.83)              3,214 (29.24)   0.13       3,149 (29.64)          3,137 (29.53)          0.00                       
  Underlying medical condition                                                                                                                                                                
                                 Hypertension                 26,685 (49.42)              5,135 (46.72)   0.04       \<0.0001               5,058 (47.61)          4,989 (46.96)   0.01       \<0.0001
                                 DM                           14,656 (27.15)              3,090 (28.11)   −0.02      0.0377                 2,993 (28.17)          2,975 (28.00)   0.00       \<0.0001
                                 Dyslipidemia                 14,653 (27.14)              3,094 (28.15)   −0.02      0.0302                 3,041 (28.62)          3,006 (28.29)   0.01       \<0.0001
                                 Previous stroke, all type    3,968 (7.35)                1,024 (9.32)    −0.06      \<0.0001               993 (9.35)             969 (9.12)      0.02       \<0.0001
                                 CHF                          1,728 (3.20)                526 (4.79)      −0.07      \<0.0001               505 (4.75)             493 (4.64)      0.02       \<0.0001
                                 ESRD                         2,340 (4.33)                563 (5.12)      −0.03      0.0003                 532 (5.01)             538 (5.06)      −0.01      \<0.0001
                                 History of malignancy        1,363 (2.52)                317 (2.88)      −0.02      0.0303                 312 (2.94)             304 (2.86)      0.02       \<0.0001
  Charlson comorbidity score     1 (0--2)                     1 (0--2)                    −0.04           \-         1 (0--2)               1 (0--2)               0.01            \-         
                                 ≤1                           36,729 (68.03)              7,287 (66.3)    0.03       0.0005                 7,006 (65.95)          7,054 (66.40)   −0.01      0.8917
                                 2--3                         10,364 (19.20)              2,149 (19.55)   −0.01      2,091 (19.68)          2,078 (19.56)          0.00                       
                                 4--5                         4,821 (8.93)                1,082 (9.84)    −0.03      1,068 (10.05)          1,041 (9.80)           0.01                       
                                 ≥6                           2,077 (3.85)                473 (4.30)      −0.02      459 (4.32)             451 (4.25)             0.00                       
  Type of stent                                                                                           \<0.0001                                                                 0.1590     
                                 BMS                          2,262 (4.19)                592 (5.39)      −0.05      514 (4.84)             573 (5.39)             −0.02                      
                                 1st generation DES           14,902 (27.60)              4,044 (36.79)   −0.16      3,948 (37.16)          3,887 (36.59)          0.01                       
                                 2nd generation DES           36,827 (68.21)              6,355 (57.82)   0.18       6,162 (58.00)          6,164 (58.02)          0.00                       
  Number of stents                                                                                        0.7611                                                                   0.4762     
                                 1                            44,670 (82.74)              9,088 (82.69)   0.00       8,736 (82.23)          8,786 (82.70)          −0.01                      
                                 2                            6,096 (11.29)               1,228 (11.17)   0.00       1,196 (11.26)          1,188 (11.18)          0.00                       
                                 ≥3                           3,225 (5.97)                675 (6.14)      −0.01      692 (6.51)             650 (6.12)             0.01                       
  Followed medication                                                                                                                                                                         
                                 Dual antiplatelet agent      31,584 (58.50)              6,745 (61.37)   −0.05      \<0.0001               6,686 (62.93)          6,725 (63.30)   −0.01      0.0001
                                 Aspirin users                15,556 (28.81)              2,693 (24.50)   0.08       2,653 (24.97)          2,690 (25.32)          −0.01                      
                                 Clopidogrel users            6,363 (11.79)               1,008 (9.17)    0.07       983 (9.25)             1,007 (9.48)           −0.01                      
                                 No antiplatelet agents       488 (0.90)                  545 (4.96)      −0.23      302 (2.84)             202 (1.90)             0.05                       
                                 RAAS blocker                 39,369 (72.92)              6,089 (55.40)   0.31       \<0.0001               6,163 (58.01)          6,082 (57.25)   0.01       \<0.0001
                                 CCB                          4,192 (7.76)                1,026 (9.33)    −0.05      \<0.0001               1,024 (9.64)           1,015 (9.55)    0.01       \<0.0001
                                 Statin                       46,501 (86.13)              7,991 (72.70)   0.29       \<0.0001               8,061 (75.88)          7,979 (75.10)   0.01       \<0.0001
                                 High intensity statin        11,962 (22.16)              1,541 (14.02)   0.17       \<0.0001               1,505 (14.17)          1,521 (14.32)   −0.01      \<0.0001
                                 Thiazide                     2,580 (4.78)                569 (5.18)      −0.02      0.0762                 598 (5.63)             561 (5.28)      0.05       \<0.0001
                                 Loop diuretics               5,535 (10.25)               1,195 (10.87)   −0.02      0.0515                 1,232 (11.60)          1,184 (11.14)   0.03       \<0.0001
                                 Spironolactone               3,014 (5.58)                612 (5.57)      0.00       0.9528                 609 (5.73)             604 (5.69)      0.01       \<0.0001
                                 Vasodilators                 18,320 (33.93)              4,088 (37.19)   −0.06      \<0.0001               4,069 (38.30)          4,035 (37.98)   0.01       \<0.0001

Values are expressed as median (interquartile range) or number (%).

BMS = bare metal stent; CCB = calcium channel blocker; CHF = congestive heart failure; DES = drug-eluting stent; DM = diabetes mellitus; ESRD = end-stage renal disease; RAAS = Renin-angiotensin-aldosterone system; SD = standard deviation.

###### Univariate and multivariate predictors of composite outcomes (all-cause mortality, MI or stroke) after coronary stenting in MI
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  Risk factors                   Univariate                  Multivariate                                                           
  ------------------------------ --------------------------- -------------- -------------- ---------- -------------- -------------- ----------
  Age                            1.057                       1.055--1.059   \<0.0001       1.045      1.042--1.047   \<0.0001       
  Male                           0.580                       0.549--0.612   \<0.0001       1.168      1.099--1.241   \<0.0001       
  Study enrollment                                                                                                                  
                                 2005--2008                  1              \-             \-         1              \-             \-
                                 2009--2011                  0.845          0.794--0.901   \<0.0001   1.155          1.063--1.254   0.0006
                                 2012--2014                  0.746          0.700--0.794   \<0.0001   1.050          0.955--1.153   0.3122
  Underlying medical condition                                                                                                      
                                 Hypertension                1.987          1.881--2.099   \<0.0001   1.167          1.095--1.245   \<0.0001
                                 DM                          1.867          1.770--1.969   \<0.0001   1.215          1.131--1.304   \<0.0001
                                 Dyslipidemia                1.239          1.171--1.311   \<0.0001   0.895          0.840--0.952   0.0005
                                 Previous stroke, all type   2.956          2.767--3.158   \<0.0001   1.498          1.388--1.616   \<0.0001
                                 Previous MI                 2.239          2.027--2.473   \<0.0001   1.246          1.124--1.380   \<0.0001
                                 CHF                         2.761          2.542--2.999   \<0.0001   1.327          1.212--1.453   \<0.0001
                                 History of malignancy       2.190          1.952--2.457   \<0.0001   1.293          1.133--1.476   0.0001
  Charlson comorbidity score     1.214                       1.202--1.227   \<0.0001       1.038      0.994--1.083   0.0905         
                                 ≤1                          1              \-             \-         1              \-             \-
                                 2--3                        1.663          1.557--1.776   \<0.0001   1.065          0.957--1.185   0.2465
                                 4--5                        2.435          2.259--2.625   \<0.0001   1.115          0.935--1.330   0.2252
                                 ≥6                          3.565          3.260--3.899   \<0.0001   1.191          0.894--1.589   0.2327
  Type of stent                                                                                                                     
                                 BMS                         1              \-             \-         1              \-             \-
                                 1st generation DES          0.853          0.760--0.956   0.0063     0.824          0.731--0.928   0.0014
                                 2nd generation DES          0.624          0.558--0.697   \<0.0001   0.634          0.563--0.715   \<0.0001
  Number of stents                                                                                                                  
                                 1                           1              \-             \-         1              \-             \-
                                 2                           1.047          0.964--1.138   0.2731     0.913          0.840--0.992   0.0323
                                 ≥3                          1.187          1.072--1.314   0.0010     0.925          0.828--1.034   0.1698
  Followed medication                                                                                                               
                                 Dual antiplatelet agent     3.949          3.622--4.306   \<0.0001   3.657          3.352--3.99    \<0.0001
                                 Aspirin users               1              \-             \-         1              \-             \-
                                 Clopidogrel users           1.284          1.118--1.474   0.0004     1.155          1.005--1.327   0.0418
                                 No antiplatelet agents      6.430          5.715--7.233   \<0.0001   2.847          2.513--3.224   \<0.0001
                                 RAAS blocker                0.561          0.532--0.591   \<0.0001   0.733          0.692--0.777   \<0.0001
                                 CCB                         0.789          0.708--0.879   \<0.0001   0.693          0.621--0.774   \<0.0001
                                 Statin                      0.360          0.341--0.379   \<0.0001   0.502          0.473--0.534   \<0.0001
                                 High intensity statin       0.799          0.745--0.857   \<0.0001   1.187          1.102--1.278   \<0.0001
                                 Thiazide                    0.907          0.795--1.035   0.1458     0.826          0.722--0.944   0.0051
                                 Loop diuretics              2.294          2.146--2.452   \<0.0001   1.349          1.250--1.457   \<0.0001
                                 Spironolactone              1.948          1.778--2.135   \<0.0001   1.278          1.154--1.416   \<0.0001
                                 Vasodilators                1.076          1.018--1.138   0.0096     1.009          0.953--1.069   0.7480
                                 Regular user                1              \-             \-         1              \-             \-
                                 Irregular user              1.983          1.867--2.105   \<0.0001   1.316          1.230--1.407   \<0.0001
                                 No user                     1.853          1.726--1.990   \<0.0001   1.380          1.282--1.485   \<0.0001

BMS = bare metal stent; CI = confidence interval; CCB = calcium channel blocker; CHF = congestive heart failure; DES = drug-eluting stent; DM = diabetes mellitus; ESRD = end-stage renal disease; HR = hazard ratio; MI = myocardial infarction; RAAS = Renin-angiotensin-aldosterone system; SD = standard deviation.

###### Outcomes after matching

![](kcj-50-499-i006)

  Patterns of beta blocking              Regular user   Non-user   HR of regular user   95% CI      p                                      
  -------------------------------------- -------------- ---------- -------------------- ----------- ------- ------- ------- -------------- --------
  All death                              1,873.32       345        3.70                 2,952.40    525     5.53    0.825   0.720--0.946   0.0060
  Followed MI                            1,151.14       212        2.22                 1,608.35    286     3.02    0.900   0.836--0.969   0.0052
  Followed stroke                        955.67         176        1.88                 894.15      159     1.72    0.903   0.839--0.972   0.0068
  Composite of MI or stroke              2,095.95       386        4.04                 2,496.88    444     4.67    0.897   0.833--0.966   0.0038
  Composite of all death, MI or stroke   3,871.53       713        7.41                 5,269.33    937     9.62    0.965   0.926--1.006   0.0938
  Revascularization                      7,422.70       1,367      13.36                8,261.09    1,469   14.61   0.960   0.921--1.000   0.0508
  All re-hospitalization                 24,733.27      4,555      46.91                25,396.24   4,516   46.69   0.951   0.913--0.991   0.0173

CI = confidence interval; HR = hazard ratio; MI = myocardial infarction.

DISCUSSION
==========

The present study was designed to evaluate whether regular beta blocker use might be associated with improved clinical outcome compared with no beta blocker use in patients with AMI treated with PCI. In this nationwide ischemic cohort study, regular beta blocker prescription improved 2 years clinical outcomes.

Beta-blocker have been reported to reduce fatal arrhythmia, ischemia or infarct size and mortality including sudden cardiac death in AMI patients, but most studies had performed in the pre reperfusion era.[@B4][@B9][@B10][@B11][@B12][@B13] Current guidelines differ in their recommendations for the use of beta blocker after AMI. 2014 American Heart Association (AHA)/American College of Cardiology (ACC) guideline for non-ST elevation acute coronary syndrome suggests that beta blocker therapy is recommended in patients with reduced systolic function as class I, level of evidence C and in patients with normal left ventricular (LV) function as class IIa, level of evidence C.[@B14] 2013 AHA/ACC guideline for ST-elevation myocardial infarction (STEMI) suggests that beta blocker should be continued during and after hospitalization for all patients and with no contraindications.[@B15] Similarly, 2017 European Society of Cardiology (ESC) guideline for STEMI suggests that routine oral beta blocker treatment should be considered during and after hospitalization in all patients without contraindications (Class IIa, level of evidence C).[@B16] 2011 AHA/American College of Cardiology Foundation (ACCF) Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease recommended beyond 3 years of beta blocker therapy in AMI patients with normal LV function.[@B17] There is no randomized controlled trial to show the efficacy of beta blocker in PCI era. Evidence supporting routine beta blocker therapy following by AMI was lacking in reperfusion era. Beta-blockers did not reduce mortality at 1 year after AMI in patients with heart failure or ventricular dysfunction.[@B5] However, only approximate half of enrolled patients underwent coronary intervention and prescription data was based on point at discharge. A recent meta-analysis which included studies since 2000 showed that beta blocker therapy was not associated to reduce mortality following AMI.[@B18] Conversely, from a registry data, beta blocker at discharge significantly reduced all cause death at 1 year after STEMI in patients treated primary PCI.[@B6] The results from previous studies are inconsistent. Our result of all comer nationwide KNHI database was in line with recommendations from current guidelines for beta blockers therapy in patients with AMI, even after PCI.

Effective duration of beta blocker therapy after AMI has been still unveiled. A single center retrospective study investigated the effect of beta blocker according to the durations of prescription on clinical outcome.[@B19] Beta-blocker therapy after AMI had beneficial effect until 1 years with 29% of mortality reduction, but beta blocker prescription at 1 and 3 years after AMI could not reduce mortality. In addition, 5-year mortality was not significantly decreased in patients who were taking beta blockers at 1 year.[@B20] Most studies had performed based on the information of medication at discharge or small sample size. A few studies tried to provide data of medication at some period point, but not of continued use of the beta blocker. In this study, it is meaningful to compare the patients who were consistently prescribed during follow-up period with patients who never prescribed beta blockers. In contemporary reperfusion era, early revascularization, antiplatelet therapy, ARB or ACE inhibitor, and lipid lowering therapy may likely attenuate the mortality benefit of beta blockers in post AMI. However, this nationwide cohort study showed that beta blocker therapy was associated with mortality reduction at least for 2 years in AMI patients treated with PCI.

A number of limitations must be acknowledged in this study. First of all, there was raised question about the accuracy of the AMI definition using the KCD-10 codes in KNIH claims database. AMI was validated in a previous study with the accuracy of 73%.[@B21] However, we defined AMI as if patients underwent PCI with AMI diagnosis so that the accuracy of diagnosis might be much higher. Diagnosis of AMI was not differentiated into STEMI and non-STEMI due to intrinsic limitation of database. Also, death was defined as the situational status, including hospital death and out of hospital death based on the loss of KNIH qualification. There was a chance of not accurate diagnosis. Uncontrolled covariates may exist. Secondly, this study was not a result of a randomized controlled trial. Consequently, the risk factors not included in the parameters could potentially affect the result. For example, patients who did not receive beta blocker were sicker or at higher risk. Furthermore, we defined regular use as MPR ≥80% but true drug adherence would depend on each patient. There is a possibility to overestimate the effect of beta blocker. Third, we could not adjust several variables, such as LV ejection fraction and time point of primary PCI in patients with STEMI, due to the intrinsic limitation of database. Even though we tried to adjust LV systolic dysfunction using prescription of loop diuretics and spironolactone, the results could be affected by LV function. Despite these limitations, the strength of this study is a large population based all comer dataset to determine the role of beta blocker after PCI in patients with AMI.

In conclusion, use of beta blocker in patients with AMI after PCI was subsequently increased from 2005 to 2014 in Korea. Regular use of beta blocker for 2 years after PCI in AMI patients was associated with improved clinical outcomes compared to no use of beta blocker.

**Funding:** This study was supported by a grant from the Korean Society of Cardiology (201605-03) and Severance Hospital (4-2015-0700, 4-2018-0136). We thank you for J. Hwang, who is a professor of division of mathematics and big data science, Daegu University, Gyeongsan, Korea, to support statistical analysis.

**Conflict of Interest:** The authors have no financial conflicts of interest.

**Author Contributions:** **Conceptualization:** Won H, Suh Y, Ko YG, Hong MK.**Data curation:** Suh Y.**Formal analysis:** Won H, Hong MK.**Funding acquisition:** Won H, Hong MK.**Investigation:** Won H, Suh Y, Kim GS, Hong MK.**Methodology:** Won H, Suh Y, Kim GS, Ko YG, Hong MK.**Project administration:** Won H, Hong MK.**Resources:** Won H, Hong MK.**Software:** Hong MK.**Supervision:** Hong MK.**Validation:** Won H, Suh Y.**Writing - original draft:** Won H.**Writing - review & editing:** Won H, Suh Y, Kim GS, Ko YG, Hong MK.

SUPPLEMENTARY MATERIAL
======================

###### Supplementary Table 1

Definition of variables (KCD codes)
